Other recognized motor signs and symptoms include gait and posture disturbances such as festination (rapid shuffling steps and a forward-flexed posture when walking), speech and swallowing disturbances including voice disorders, masklike face expression or small handwriting, although the range of possible motor problems that can appear is large
And so FDA is going to need to use a different lens. Unlike FDA approval of a new drug, which requires years of clinical trials demonstrating safety and effectiveness, placement on the 503A Bulks List answers a different regulatory question
GHK-CU is a naturally occurring copper-binding tripeptide composed of glycine, histidine, and lysine
Patent 6,335,319
My assumption is that, within the next 12-18 months, we will get something from [big] pharma and the FDA stating that a select amount [of peptides] will most likely be deemed Class 1 [from their current Class 2], which will mean that theyre legal to compound [in the U.S